Amgen (AMGN) Tops Q2 EPS by 38c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Amgen Reports Second Quarter 2019 Financial Results
July 30, 2019 4:01 PM EDTTHOUSAND OAKS, Calif., July 30, 2019 /PRNewswire/ --Â Amgen (NASDAQ: AMGN) today announced financial results for the second quarter of 2019. Key results include:
Total revenues decreased 3% to $5.9 billion in comparison to the second quarter of 2018 reflecting increasing competition due to patent expirations. Product sales declined 2% globally. Prolia® (denosumab), Repatha® (evolocumab), Parsabiv® (etelcalcitide) and Aimovig® (erenumab-aooe) units grew double-digits or better.GAAP earnings per share (EPS) increased 3% to $3.57 benefited by lower weighted-average shares outstanding. GAAP operating income decreased 5% to $2.7 billion and GAAP operating margin decreased 1.9 percentage... More